Several studies have demonstrated that pioglitazone treatment, besides improving insulin sensitivity, reduces chronic inflammation in T2DM patients, which is manifested by a decrease in the levels of TNF-α, IL-6, high-sensitivity C-reactive protein (CRP) (hsCRP), leptin, and other inflammatory markers (15). The gene discussed is INS; the disease is type 2 diabetes mellitus.